Bharat Biotech concludes Covaxin's final analysis; claims 77.8% efficacy in phase-3 trial

Bharat Biotech said early on Saturday that it has concluded the final analysis for its COVID-19 vaccine Covaxin as part of phase-3 clinical trials.

Sharing the final phase-3 pre-print data on medRxiv, the Hyderabad-based pharma company claimed that its indigenous jab demonstrates an overall efficacy of 77.8% against symptomatic infection.